Published in Top HIV Med on December 01, 2009
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis (2011) 3.04
Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS (2010) 2.33
Diagnosing and responding to violations in the positivity assumption. Stat Methods Med Res (2010) 2.29
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS (2011) 2.22
Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A (2010) 2.16
HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Clin Infect Dis (2011) 2.08
Antiretroviral treatment strategies in highly treatment experienced perinatally HIV-infected youth. Pediatr Infect Dis J (2012) 1.62
Drug resistance is widespread among children who receive long-term antiretroviral treatment at a rural Tanzanian hospital. J Antimicrob Chemother (2010) 1.60
HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother (2010) 1.53
Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives? J Int AIDS Soc (2011) 1.36
Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc Natl Acad Sci U S A (2011) 1.33
Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient. Antivir Ther (2011) 1.32
Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses (2011) 1.22
Phylogenetic insights into regional HIV transmission. AIDS (2012) 1.18
Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors. Proc Natl Acad Sci U S A (2011) 1.18
Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission. AIDS Res Hum Retroviruses (2011) 1.17
Sequence quality analysis tool for HIV type 1 protease and reverse transcriptase. AIDS Res Hum Retroviruses (2011) 1.16
Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antiviral Res (2010) 1.15
Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti. J Int AIDS Soc (2012) 1.11
HIV type 1 Gag as a target for antiviral therapy. AIDS Res Hum Retroviruses (2011) 1.08
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease. Antimicrob Agents Chemother (2010) 1.08
Genotyping external quality assurance in the World Health Organization HIV drug resistance laboratory network during 2007-2010. Clin Infect Dis (2012) 1.06
Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr (2011) 1.04
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Agents Chemother (2010) 1.04
Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors. Retrovirology (2010) 1.03
The "Connection" Between HIV Drug Resistance and RNase H. Viruses (2010) 1.00
Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens. Antimicrob Agents Chemother (2011) 0.98
Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa. J AIDS Clin Res (2011) 0.96
Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings. AIDS Res Treat (2011) 0.96
In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile. Antimicrob Agents Chemother (2011) 0.96
K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism. PLoS One (2011) 0.95
A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences. AIDS Res Ther (2010) 0.93
Gender inequities in quality of care among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000-2010). PLoS One (2014) 0.93
Short communication: Transmitted drug resistance and molecular epidemiology in antiretroviral naive HIV type 1-infected patients in Rhode Island. AIDS Res Hum Retroviruses (2010) 0.92
Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan. J Clin Microbiol (2011) 0.92
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. Antimicrob Agents Chemother (2010) 0.90
How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa? AIDS (2014) 0.90
Directly observed antiretroviral therapy in substance abusers receiving methadone maintenance therapy does not cause increased drug resistance. AIDS Res Hum Retroviruses (2010) 0.90
Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa. J Int AIDS Soc (2013) 0.90
Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C. Retrovirology (2010) 0.89
In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043. Antimicrob Agents Chemother (2010) 0.88
Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine. Antimicrob Agents Chemother (2010) 0.87
Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa. AIDS Res Hum Retroviruses (2011) 0.87
The L76V drug resistance mutation decreases the dimer stability and rate of autoprocessing of HIV-1 protease by reducing internal hydrophobic contacts. Biochemistry (2011) 0.86
Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design. Curr Top Med Chem (2011) 0.85
Recursive partitioning of resistant mutations for longitudinal markers based on a U-type score. Biostatistics (2011) 0.85
HIV-1 drug resistance testing from dried blood spots collected in rural Tanzania using the ViroSeq HIV-1 Genotyping System. J Antimicrob Chemother (2010) 0.85
Dynamical basis for drug resistance of HIV-1 protease. BMC Struct Biol (2011) 0.85
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring. Antimicrob Agents Chemother (2011) 0.84
Outcomes of Universal Access to Antiretroviral Therapy (ART) in Georgia. AIDS Res Treat (2011) 0.84
Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. BMC Med Res Methodol (2012) 0.83
Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr (2011) 0.83
An update on the use of Atripla in the treatment of HIV in the United States. HIV AIDS (Auckl) (2010) 0.83
Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease. ACS Chem Biol (2012) 0.82
Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population. BMC Infect Dis (2012) 0.80
Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy. Antimicrob Agents Chemother (2010) 0.80
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis. AIDS Patient Care STDS (2014) 0.79
"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice. PLoS One (2011) 0.79
Directly administered antiretroviral therapy for HIV-infected individuals in opioid treatment programs: results from a randomized clinical trial. PLoS One (2013) 0.79
TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors. Antimicrob Agents Chemother (2011) 0.79
The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy. AIDS Res Ther (2014) 0.79
HIV prevalence and route of transmission in Turkish immigrants living in North-Rhine Westphalia, Germany. Med Microbiol Immunol (2011) 0.78
Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programs. BMC Infect Dis (2011) 0.78
Differences in the interactions between the subunits of photosystem II dependent on D1 protein variants in the thermophilic cyanobacterium Thermosynechococcus elongatus. J Biol Chem (2010) 0.78
Mutual information analysis reveals coevolving residues in Tat that compensate for two distinct functions in HIV-1 gene expression. J Biol Chem (2012) 0.78
Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study. J Infect Dis (2011) 0.77
Molecular Epidemiology and Transmission Dynamics of Recent and Long-Term HIV-1 Infections in Rural Western Kenya. PLoS One (2016) 0.77
Detection of HIV-1 dual infections in highly exposed treated patients. Virol J (2011) 0.77
Virological failure of staggered and simultaneous treatment interruption in HIV patients who began Efavirenz-based regimens after allergic reactions to nevirapine. AIDS Res Ther (2013) 0.77
Measuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testing. PLoS One (2011) 0.76
Prevalence of drug resistance and associated mutations in a population of Hiv-1+ Puerto Ricans in 2005. Bol Asoc Med P R (2013) 0.75
HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds. J Acquir Immune Defic Syndr (2015) 0.75
Evaluation of novel Saquinavir analogs for resistance mutation compatibility and potential as an HIV-Protease inhibitor drug. Bioinformation (2014) 0.75
The HIVToolbox 2 web system integrates sequence, structure, function and mutation analysis. PLoS One (2014) 0.75
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med (2008) 7.31
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med (2004) 6.87
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis (2008) 5.14
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis (2003) 4.51
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med (2013) 4.26
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS (2007) 3.94
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis (2005) 3.93
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis (2007) 3.75
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med (2008) 3.66
2011 update of the drug resistance mutations in HIV-1. Top Antivir Med (2011) 3.66
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One (2013) 3.53
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis (2005) 3.47
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One (2009) 3.40
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis (2009) 3.37
Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus. Emerg Infect Dis (2013) 3.35
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med (2014) 3.24
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA (2006) 3.23
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis (2008) 3.15
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA (2011) 3.08
Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med (2006) 3.06
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis (2007) 3.05
Genetic analysis reveals the complex structure of HIV-1 transmission within defined risk groups. Proc Natl Acad Sci U S A (2005) 3.04
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04
Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog (2009) 2.92
Update of the Drug Resistance Mutations in HIV-1. Top HIV Med (2008) 2.91
Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91
Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology (2010) 2.90
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev (2008) 2.88
HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis (2005) 2.86
Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol (2005) 2.83